Antidiabetic drugs, fasting glucose levels, and achievement of fasting glucose <7 mmol/L in patients with psychotic disorders and control subjects*
| Patients with psychosis | Fasting glucose (mmol/L) | Control subjects† | Fasting glucose (mmol/L) | |||
|---|---|---|---|---|---|---|
| Antidiabetic drugs | Mean (range) | <7.0 mmol/L | Mean (range) | <7.0 mmol/L | ||
| Number of participants | 40 | 38 | ||||
| One oral antidiabetic drug | 19 (48) | 8.5 (4.9–15.4) | 6 (32) | 18 (47) | 7.7 (6.2–11.1) | 5 (28) |
| Metformin | 13 (68) | 7.4 (4.9–12.4) | 6 (46) | 11 (61) | 7.6 (6.2–9.7) | 2 (18) |
| Glibenclamide | 4 (21) | 11.3 (7.2–15.4) | 0 (0) | 5 (28) | 7.5 (6.3–11.1) | 3 (60) |
| Other‡ | 2 (11) | 10.2 (8.2–12.1) | 0 (0) | 2 (11) | 8.9 (7.6–10.1) | 0 (0) |
| ≥Two oral antidiabetic drugs | 3 (8) | 8.5 (6.3–12.7) | 2 (67) | 6 (16) | 9.1 (7.7–10.0) | 0 (0) |
| Insulin | 18 (45) | 9.4 (3.2–23.6) | 5 (28) | 14 (37) | 8.2 (3.9–14.0) | 7 (50) |
*Data reported as number, number (%), or mean (range, minimum–maximum). Treatment goal was fasting glucose <7.0 mmol/L.
†Control subjects who developed diabetes during the follow-up period.
‡Glimepiride, repaglinide, or glipizide.